Lexpert Special Editions

Lexpert Special Edition on Health Sciences

The Lexpert Special Editions profiles selected Lexpert-ranked lawyers whose focus is in Corporate, Infrastructure, Energy and Litigation law and relevant practices. It also includes feature articles on legal aspects of Canadian business issues.

Issue link: https://digital.carswellmedia.com/i/1379015

Contents of this Issue

Navigation

Page 17 of 43

16 www.lexpert.ca Feature HEALTH SCIENCES IP IS THRIVING IT'S BEEN a tough year (and then some), but the health sciences sector has been thriving during the pandemic. Obtaining and defending patents has been a critical part of that success. Daphne Lainson, chairwoman of Smart & Biggar LLP, says both biopharma — which are drugs created from biological sources — and classic small-molecule phar- maceuticals are strong globally and from her firm's observation. Innovators — pharmaceutical companies that discover and develop new medicines — have been very active across the board, says Lainson, with breakthrough oncolog y treat- ments. "e biopharma industry as a whole is very strong and has been innovating throughout — even though things are not in their usual pattern." is activity — along with expected patented medicine pricing regime changes and COVID-19 — is shaping intellectual property law in the health sciences now. What's new? Since Health Canada has fast-tracked the authorization process for needed medical devices and diagnostic tools, hand sanitizers and disinfectants to combat the spread of COVID-19, there are new regulatory, adver- tising and marketing regimes to navigate. ere are also patent and trademark protec- tions for this new environment. "ings are moving more quickly, at least these days, with respect to certain types of products [for] COVID," says Marc Richard, a partner at Gowling WLG (Canada) LLP in Ottawa. "Because of the speed at which these prod- ucts are being brought to market and the types of product . . . it's more of a challenge to fit within how our laws are structured and how our system works," he says. ere is also more movement in the psychedelic space, says Micheline Gravelle, the life sciences practice group leader at Bereskin & Parr LLP in Toronto. Research continues with "magic mush- rooms," which contain psilocybin, an agent researchers believe could help treat drug dependence, anxiety and mood disorders. e THE SUCCESS OF BIOPHARMA, THE REVISED PATENTED MEDICINE PRICING REGIME AND THE CHANGES WROUGHT BY COVID-19 ARE ALL SHAPING INTELLECTUAL PROPERTY LAW IN THE HEALTH SCIENCES

Articles in this issue

Links on this page

Archives of this issue

view archives of Lexpert Special Editions - Lexpert Special Edition on Health Sciences